robot_hair
Member
- Reaction score
- 4
One word of caution;
http://www.cassiopea.com/activities/product-pipeline/winlevi.aspx
This was at 1%. So when you going to use 5%, it might be wise to keep certain things in check. Let me tell you that long term HPA axis supression isn't particularly healthy.
I would assume that at 5% more people will be hit with HP axis changes, due to higher systemic absorption. As you can read this was at 1%;
Here is the full quote:
SAFETY
No clinically relevant safety issues were noted with any of the concentrations of Winleviâ„¢ tested and no clinically relevant signs of the typical Local Skin Reactions (LSR) generally associated with corticosteroids use were appreciated. In the HPA / PK study only 3 out of 42 subjects resulted borderline in the lab test relevant to HP axis, with no sign of clinical corticosteroid specific adverse events.
Based on safety to date, and low levels of systemic exposure, FDA granted a waiver for the typically required systemic 2-year carcinogenicity study.
To further explain: "Winlevi" is an acne drug owned by Cassiopea. Cassiopea also owns CB, which they are now calling "Breezula". Winlevi and Breezula are either very similar, or just the same drug under two different names.
Sadly, I don't completely understand the above quote, especially what the word "borderline" means here. (Maybe Swoop or someone else can explain further.)
So if its no better than RU, why not use RU instead? It's much cheaper and MAYBE safer.
There is also a hope that the side effects may be even less than RU, possibly through less systemic absorption. And there have been rumblings for a while that RU stops working after a while, but it is unclear if this is true.
Swoop said:So when you going to use 5%, it might be wise to keep certain things in check.
Do you mean that one should have a doctor periodically check certain levels, or something else?